Orange Grove Bio strives to positively transform the quality of life of patients with cancer, autoimmune and inflammatory diseases by expediting the development of new medical breakthroughs.

“I look forward to contributing my deep expertise in therapeutic development and cancer research to support Orange Grove Bio’s vision of creating biotechnology companies that will develop the transformative medicines of tomorrow.”

– John C. Byrd, M.D., Renowned Cancer Clinician and Researcher, Chair and Professor for the Department of
Internal Medicine at the University of Cincinnati College of Medicine

We focus on partnerships with research institutions and universities which, along with our network of co-investors, operations, and research & development teams, allows us to streamline the technology licensing process and expedite drug development to make a  positive impact on patients and their communities.


Direct Sourcing Process

Our university partnerships and close relationships with scientists and clinicians provide us with unique opportunities to identify and license promising biomedical innovation


Comprehensive Diligence Process

A multi-stage process through hypothesizing the clinical and financial efficacy of each asset in conjunction with the Principal Investigator, their team, and Orange Grove Bio’s team of Biology PhDs and venture partners.


Seasoned Operations Teams

Comprised of industry experts, we leverage their decades of expertise in navigating pharmaceutical assets through the clinical process and driving scientific and finance operations.


In The News

Orange Grove Bio Sets Sights on Rapidly Emerging Middle East Biotech Ecosystem through New Academic Collaboration with Weizmann Institute of Science

Partnership represents firm’s second international collaboration and provides access to groundbreaking research taking place within world’s fifth largest pharmaceutical market The following excerpt was taken from GlobeNewswire – continue reading here. CINCINNATI, January 31, 2023 (GLOBE NEWSWIRE) – Orange Grove Bio, a drug investment and development firm, today announced that it has established a new

Read Article

Thani Al Zeyoudi attends World Investment Forum to accelerate investment in high-potential markets

The following excerpt was taken from — continue reading here. ABU DHABI, 19th October, 2023 (WAM) – Dr Thani bin Ahmed Al Zeyoudi, UAE Minister of State for Foreign Trade, has held a series of high-level meetings with global ministers on the fourth day of the 8th World Investment Forum (WIF), during which he

Read Article

Orange Grove Bio Subsidiary Awarded $2.05 Million SBIR Phase II Grant to Advance Development of Novel Platelet Preservation Technology

OGB Also Announces Key Appointments to Board of Senior Advisors and the Opening of New Headquarters The following excerpt was taken from GlobeNewswire – continue reading here. CINCINNATI, Sept. 28, 2023 (GLOBE NEWSWIRE)  Orange Grove Bio (OGB), a drug investment and development firm, today announced that Preservation Bio, one of the firm’s majority-owned subsidiaries, has been

Read Article

From The Patient's Eyes Podcast

From The Patient’s Eyes: Erin Schwindenhammer

Erin Schwindenhammer, a patient diagnosed with autoimmune diseases.


From The Patient’s Eyes: Adriana Trama

Adriana Trama, a patient suffering from Crohn’s Disease and Ulcerative Colitis.


From The Patient’s Eyes: Julianne Larkin

Julianne Larkin, a patient suffering from Graves’ disease and arthritis.